Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8899 results

  1. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Withdrawn guidance

  2. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance

  3. Implantable cardioverter defibrillators for arrhythmias (TA95)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  4. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1064

    Withdrawn guidance

  5. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

    Withdrawn guidance

  6. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Withdrawn guidance

  7. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  8. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Withdrawn guidance

  9. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  10. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1045.

    Withdrawn guidance

  11. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1054.

    Withdrawn guidance

  12. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Withdrawn guidance

  13. Immunosuppressive therapy for renal transplantation in adults (TA85)

    This guidance has been updated and replaced by NICE technology appraisal guidance 481.

    Withdrawn guidance

  14. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

    Withdrawn guidance

  15. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1015.

    Withdrawn guidance